Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Opinions Op-Ed

AI’s Greatest Threat Is Biological, Not Robotic: 70% of Security Experts Warn AI Increases Bioweapon Risk; DNA Screening Evasion Possible

by Team Lumida
September 17, 2026
in Op-Ed
Reading Time: 4 mins read
A A
0
AI’s Greatest Threat Is Biological, Not Robotic: 70% of Security Experts Warn AI Increases Bioweapon Risk; DNA Screening Evasion Possible
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • The greatest existential threat from AI is biological rather than robotic, according to Bloomberg Opinion columnist Gautam Mukunda. Anthropic researcher Jacob Coxon recently quit, stating that AI developers “earnestly believe that it could kill us all by the end of the decade.” Evan Hubinger (Anthropic) put extinction odds above 10% in next 10 years. An Institute for Security and Technology survey found 70% of 111 national security practitioners believe AI meaningfully increases bioweapon risk.
  • AI-enabled researchers could make pathogens far more deadly: the same mechanism Australian researchers accidentally created in mice 25 years ago without AI (mousepox with interleukin-4 gene suppressing immune response) could be rapidly engineered using AI. Microsoft-led team demonstrated AI protein design tools can already produce DNA sequences that evade screening software, though whether those sequences would function as weapons remains unproven.
  • Key safeguards needed: mandate DNA synthesis screening (currently only requested, not mandated by federal government), require automated labs to work only with verified researchers from accredited institutions, implement bounty programs for AI-DNA screening improvements. Microsoft’s AI protein design tools have already shown capability to evade current screening measures, creating a race between attackers and defenders.
  • Federal government opposition is hampering safeguards: Trump White House has opposed AI regulation and dissolved the National Counterproliferation and Biosecurity Center and DHS counter-WMD office. Revised screening framework has been in limbo for 16 months. Private sector (particularly Anthropic) is filling the gap: Anthropic has blocked 5 attempts to use Claude for bioweapon research and warns it can no longer assume new models fall below threshold for meaningful bioweapon assistance.

What Happened?

Bloomberg Opinion columnist Gautam Mukunda published analysis arguing AI’s greatest existential risk is biological rather than robotic. Anthropic researcher Jacob Coxon quit last week citing concerns that AI could “kill us all by the end of the decade.” Evan Hubinger (Anthropic alignment science lead) estimated extinction odds above 10% in next 10 years. An Institute for Security and Technology survey found 70% of national security practitioners believe AI increases bioweapon risk. Microsoft-led team demonstrated AI protein design tools can produce DNA sequences that evade screening safeguards. Federal DNA screening mandate has been stalled 16 months; Trump administration opposes AI regulation and dissolved biosecurity centers. Anthropic reports blocking 5 attempts to use Claude for bioweapon research.

Why It Matters?

For national security policymakers, the article highlights that bioweapon risk from AI is not speculative—it’s near-term and involves gaps in federal safeguards. For Microsoft shareholders, the company’s identification as creating DNA-screening-evading AI tools raises regulatory risk. For Anthropic and other AI companies, the piece validates biosecurity work and internal safeguards as mission-critical. For the biotech industry, mandatory DNA screening would impose costs but would prevent catastrophic bioweapon-related regulation. For the venture capital ecosystem funding automated labs, the analysis suggests regulatory crackdown is likely if safeguards aren’t implemented voluntarily.

What’s Next?

Monitor federal regulation of DNA synthesis screening; if Trump administration lifts opposition and implements mandatory screening, it would validate the biosecurity argument. Watch for additional AI companies (OpenAI, Google, others) announcing bioweapon research blocking; if major labs implement similar safeguards, it would signal industry consensus on the risk. Track automated lab development; if companies implement researcher verification requirements before deployment, it would validate voluntary safeguards. Monitor biological attacks or hoaxes; if any incident occurs involving AI-aided pathogen development, it would trigger immediate industry-stifling regulation. Also watch Anthropic’s public safety disclosures; if the company releases detailed threat assessments, it would validate the seriousness of the risk and set new standards for biosecurity transparency in AI.

Affected Tickers & Coins: MSFT

Source: Bloomberg Opinion

Previous Post

Zipline Drone Delivery Startup Raises $1B at $20 Billion Valuation; Nearly Triples Valuation From $7.6B Earlier This Year

Next Post

How to Bet on Oil Without Owning a Barrel: Retail Traders Navigate Crude Products From ETFs to Perpetual Futures

Recommended For You

Headline Inflation Accelerated While the Breadth of Price Increases Narrowed, Which Is the Case for Waiting

by Team Lumida
7 days ago
OpenAI President Greg Brockman Joins Altman at Trump-Xi Dinner; $25M MAGA Inc. Donor; Strengthens OpenAI’s White House AI Policy Access

Bloomberg's editorial board argues one more quarter-point rise may not be enough. The Fed decides before it sees PCE.

Read more

A Pipeline With No Customer Contracts Just Got $42 Million of Emergency Powers Funding

by Team Lumida
7 days ago
silver iMac

The Defense Production Act was passed in 1950. Denning's warning is about who uses it next.

Read more

CVC Is on Both Sides of a €10.7 Billion Deal, and the Independent Directors Voted Against It

by Team Lumida
1 week ago
CVC Is on Both Sides of a €10.7 Billion Deal, and the Independent Directors Voted Against It

These transactions normally happen privately, where nobody can contest the price. Here public shareholders can.

Read more

Bears Outnumber Bulls by 8 Points. In 1999 Bulls Led by 20. That Is the Whole Argument Against a Bubble

by Team Lumida
1 week ago
Bears Outnumber Bulls by 8 Points. In 1999 Bulls Led by 20. That Is the Whole Argument Against a Bubble

The same column reports AI is 40% to 60% of market value and 70% of earnings growth. Both things are true.

Read more

Heat Affects 81% of Global Index Companies and Only About a Third Are Doing Anything Operational About It

by Team Lumida
1 week ago
Heat Affects 81% of Global Index Companies and Only About a Third Are Doing Anything Operational About It

MSCI puts labour productivity losses at $3.9 trillion a year. The wider estimates are much larger and much less certain.

Read more

SpaceX Is Paying $17 Billion for Spectrum From the Company That Just Went Bankrupt Using It

by Team Lumida
2 weeks ago
SpaceX Is Paying $17 Billion for Spectrum From the Company That Just Went Bankrupt Using It

EchoStar spent $46 billion attempting the same thing, never finished the network, and lost subscribers.

Read more

The World Can Build 142 Million Cars and Will Sell 85 Million, and Capacity Is Still Going Up

by Team Lumida
2 weeks ago
a person stacking coins on top of a table

Sixty-three listed automakers earned $106 billion last year. Apple earned $141 billion.

Read more

A Column Arguing You Need Gold and Bitcoin Concedes Neither Is a Safe Haven, Then Explains Why That’s the Wrong Test

by Team Lumida
2 weeks ago
A Column Arguing You Need Gold and Bitcoin Concedes Neither Is a Safe Haven, Then Explains Why That’s the Wrong Test

The author runs an ETF business that is adding digital-asset products. The argument is still worth engaging with.

Read more

Rural Inflation Is Running at 4% Against 3.6% in Cities, the Widest Gap Since 2022

by Team Lumida
2 weeks ago
Rural Inflation Is Running at 4% Against 3.6% in Cities, the Widest Gap Since 2022

Motor fuels are up 35% and household fuels 44%, and both take larger shares of budgets outside cities.

Read more

SpaceX Seeks $40 Billion for Nvidia Chips as Hyperscalers Shorten Maturities From 30% to 46% of Issuance

by Team Lumida
3 weeks ago
SpaceX Seeks $40 Billion for Nvidia Chips as Hyperscalers Shorten Maturities From 30% to 46% of Issuance

An AI cloud provider is paying 11% on a fully amortising loan. Lenders are demanding principal back rather than trusting a refinancing.

Read more
Next Post
How to Bet on Oil Without Owning a Barrel: Retail Traders Navigate Crude Products From ETFs to Perpetual Futures

How to Bet on Oil Without Owning a Barrel: Retail Traders Navigate Crude Products From ETFs to Perpetual Futures

Novo Nordisk Partners With Orbis for Oral Biologic Pills Worth $1.4B; Eli Lilly Also Stakeholder in AI Drug Design Startup

Novo Nordisk Partners With Orbis for Oral Biologic Pills Worth $1.4B; Eli Lilly Also Stakeholder in AI Drug Design Startup

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

Emerging-Market Stocks Reach Record Highs as AI Optimism Fuels Investment Surge

February 11, 2026
Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue

October 23, 2025
Fed Signals Rate Cut: What It Means for Your Investments

Warsh Walked Into the Fed Wanting to Cut Rates. Now He Has to Stop Hikes.

May 28, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018